GO
Loading...

Enter multiple symbols separated by commas

Biotech and Pharmaceuticals Life Sciences

More

  • Sunesis reports 2Q loss Thursday, 30 Jul 2015 | 7:45 AM ET

    SOUTH SAN FRANCISCO, Calif. _ Sunesis Pharmaceuticals Inc. on Thursday reported a loss of $8.9 million in its second quarter. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 13 cents per share. Four analysts surveyed by Zacks expected $1.2 million.

  • Theravance reports 2Q loss Wednesday, 29 Jul 2015 | 7:10 PM ET

    SOUTH SAN FRANCISCO, Calif. _ Theravance Inc. on Wednesday reported a loss of $7.8 million in its second quarter. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 6 cents per share. Theravance shares have risen 10 percent since the beginning of the year.

  • Vanda reports 2Q loss Wednesday, 29 Jul 2015 | 6:21 PM ET

    WASHINGTON _ Vanda Pharmaceuticals Inc. on Wednesday reported a loss of $5.4 million in its second quarter. The Washington- based company said it had a loss of 13 cents per share. Keywords: Vanda Pharmaceuticals, Earnings Report.

  • Corium reports 3Q loss Wednesday, 29 Jul 2015 | 6:15 PM ET

    MENLO PARK, Calif. _ Corium International Inc. on Wednesday reported a loss of $5.9 million in its fiscal third quarter. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 37 cents per share. Three analysts surveyed by Zacks expected $10.5 million.

  • Dyax reports 2Q loss Wednesday, 29 Jul 2015 | 5:45 PM ET

    BURLINGTON, Mass. _ Dyax Corp. on Wednesday reported a loss of $8.4 million in its second quarter. Dyax shares have risen 73 percent since the beginning of the year. Access a Zacks stock report on DYAX at http://www.zacks.com/ap/DYAX.

  • Cytokinetics reports 2Q loss Wednesday, 29 Jul 2015 | 5:24 PM ET

    SOUTH SAN FRANCISCO, Calif. _ Cytokinetics Inc. on Wednesday reported a loss of $10.6 million in its second quarter. On a per-share basis, the South San Francisco, California- based company said it had a loss of 27 cents. Cytokinetics shares have dropped 12 percent since the beginning of the year.

  • LONDON, July 29- British investor Neil Woodford is backing a start-up biopharmaceutical firm whose first venture will be to launch clinical trials of three drugs developed by Novartis. It said has raised $119 million from Woodford Investment and Invesco Perpetual among others, and has acquired drug programmes from Novartis for the treatment of brittle bone...

  • LONDON, July 28- Researchers in the United States trying to develop a vaccine against the deadly Middle East Respiratory Syndrome virus say they have had early signs of success in animal experiments. MERS, which causes coughing and fever and can lead to fatal pneumonia and kidney failure, has been reported mainly in Saudi Arabia and South Korea but has also been...

  • How effective is new malaria vaccine? Friday, 24 Jul 2015 | 11:40 AM ET
    How effective is new malaria vaccine?

    Suki Virji, analyst for Scrip Intelligence, discusses the malaria vaccine developed by GlaxoSmithKline, which has received a "green light" by the European Medicines Agency.

  • LONDON, July 24- AstraZeneca is dipping its toe in the biosimilars market, as a way to make future cancer drug cocktails more affordable, by linking with a Japanese group to develop a copy of Roche's blockbuster medicine Avastin. FKB-- itself a tie-up between Fujifilm and Kyowa Hakko Kirin-- commenced a Phase I clinical trial of its copy of Avastin, called FKB238, in...

  • July 23- Switzerland's Roche is lining up more new drugs to drive sales in a two-year window before cheap copycats of its biotech medicines hit the market, including a promising cancer immunotherapy it hopes to launch by late 2016.. The shares rose 1.1 percent by 0920 GMT on Thursday, with Deutsche Bank analyst Tim Race describing the results as "a modest positive."

  • July 23- Switzerland's Roche expects no copycat competition to its biotech cancer drugs for another two years, giving it space to grow a successful portfolio of new and established medicines. The shares rose 1.5 percent in early trading on Thursday, with Deutsche Bank analyst Tim Race describing the results as "a modest positive." Its three top-selling cancer...

  • BRIEF-NOVAVAX INC SAYS POSITIVE TOP-LINE DATA FROM PHASE 1. *Positive top-line data from phase 1 trial of ebola virus glycoprotein recombinant nanoparticle vaccine candidate adjuvanted with matrix-m. *Trial demonstrated that ebola GP vaccine was highly immunogenic, well-tolerated and resulted in significant antigen dose-sparing.

  • July 21- Amgen Inc's cholesterol fighting drug was approved by the European Commission, giving the keenly anticipated treatment a head start over a rival drug being developed by Regeneron Pharmaceuticals Inc and Sanofi SA. Amgen did not immediately reveal when the drug would be available or its pricing strategy. Amgen's drug is designed for biweekly doses of...

  • Tekmira Pharmaceuticals Corp. said last month that an experimental Ebola treatment that it was developing would probably fail in a clinical trial. The Canadian company says it will focus on experimental treatments for the hepatitis B virus and will change its name to Arbutus Biopharma Corp.. Other companies in the field included NewLink Genetics Corp.,...

  • DUBLIN, July 16- Britain's Immunocore completed Europe's largest ever financing round by a private life sciences company on Thursday, raising $320 million from investors including Eli Lilly& Co, Malin and Woodford Investment Management. The investment by some of the healthcare sector's "most highly regarded international institutions" is another...

  • July 14- Celgene Corp said on Tuesday it would buy Receptos Inc for $7.2 billion in a move that will give the U.S. biotechnology company a potential multibillion-dollar drug in late stage development for inflammatory bowel disease and multiple sclerosis. The Receptos move comes just two weeks after Celgene said it would invest $1 billion in Juno Therapeutics...

  • UPDATE 1-Celgene to buy Receptos for $7.2 bln Tuesday, 14 Jul 2015 | 5:41 PM ET

    July 14- Celgene Corp said on Tuesday it would buy Receptos Inc for $7.2 billion in a move that will give the U.S. biotechnology company a potential blockbuster drug in late stage development for inflammatory bowel disease and multiple sclerosis. The move comes just two weeks after Celgene said it would invest $1 billion in Juno Therapeutics to gain access to...

  • LONDON, July 14- It's a showpiece drug that has the potential to end a disease that kills half a million African children a year. Backed by billionaire philanthropist Bill Gates and developed by GlaxoSmithKline, the vaccine-- called RTS, S or Mosquirix-- is being assessed by regulators and global health authorities. But it's a very complicated vaccine, so the...

  • WASHINGTON, July 9- An advisory panel to the U.S. Food and Drug Administration effectively supported approval of Eli Lilly& Co's experimental lung cancer drug necitumumab on Thursday but recommended measures be taken to mitigate the drug's risks. The panel did not officially vote but an informal poll taken by the FDA indicated most members believe the...